动脉流入道近端化治疗血液透析通路相关远端缺血
单中心回顾性队列研究纳入2017至2023年64例因血液透析通路相关远端缺血(HAIDI)接受动脉流入道近端化(PAI)的患者,85.9%完全缓解缺血症状,30天并发症率10.9%,1、12、24个月一期通畅率分别为94%、81%、71%。
要点
- PAI术后85.9%(55/64)患者缺血症状完全缓解,7.8%(5/64)部分缓解。
- 30天并发症率10.9%(7/64),其中血栓5例(7.8%)。
- 1、12、24个月一期通畅率94%、81%、71%,二期通畅率97%、87%、84%。
核心结论
- PAI是HAIDI的可靠干预选择,安全性和有效性结果与DRIL相当,尽管使用了合成移植物。
- PAI具有维持自体动脉通路的额外优势。
- 需要进一步研究PAI作为DRIL有前景的替代方案用于HAIDI管理。
研究设计与样本
- 单中心回顾性队列研究,纳入2017年至2023年因HAIDI接受PAI的64例动静脉内瘘和移植物患者。
- 多数病例使用4×7锥形聚四氟乙烯(PTFE)移植物将血液透析通路流入道连接至腋动脉。
- 主要结局为HAIDI缓解(完全、部分或无缓解),次要结局包括功能通畅率(一期和二期)和PAI术后30天并发症。
主要发现
- 64例患者平均年龄65岁(标准差15岁),女性59.4%(38/64),非裔美国人37.5%(24/64)。
- 合并症包括高血压95.3%(61/64)、冠心病50%(32/64)、糖尿病79.7%(51/64)、吸烟史43.8%(28/64)。
- PAI术后完全缓解55/64(85.9%),部分缓解5/64(7.8%),无缓解2/64(3.1%),缓解情况未知2/64(3.1%)。
- 1、12、24个月一期通畅率分别为94%、81%、71%,二期通畅率分别为97%、87%、84%。
- 30天并发症率10.9%(7/64),包括血栓5/64(7.8%)、血栓合并感染1/64(1.6%)、中心静脉狭窄继发上肢肿胀1/64(1.6%,经中心静脉系统血管成形术缓解);12和24个月因血栓失败率分别为14%(9/64)和15.6%(10/64)。
临床怎么用
- 作者认为PAI是HAIDI的可靠干预选择,安全性和有效性结果与DRIL相当。
- 作者认为PAI具有维持自体动脉通路的额外优势。
- 作者建议进一步研究PAI作为DRIL的有前景的替代方案用于HAIDI管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hemodialysis access-induced distal ischemia (HAIDI) is a known complication of hemodialysis (HD) access. Distal revascularization and interval ligation (DRIL) is the preferred treatment for HAIDI by many surgeons. Proximalization of arterial inflow (PAI) is a promising alternative technique that, unlike DRIL, preserves the native arterial inflow. The purpose of this study is to report our experience with PAI on a series of 64 patients. METHODS: This is a single-center, retrospective cohort study of patients with both arteriovenous (AV) fistulas and grafts who underwent PAI for HAIDI from 2017 to 2023. A 4 × 7 tapered polytetrafluoroethylene (PTFE) graft was used to connect HD access inflow to the axillary artery in the majority of cases. The primary outcome of the study is resolution of HAIDI (complete, partial, or no resolution). Secondary outcomes include functional patency (primary and secondary) and 30-day complications following PAI. RESULTS: Of the 71 patients identified to have had PAI between May 2017 to August 2023, seven were lost to follow-up. In total, 64 patients were included, with an average age of 65 years (standard deviation, 15 years), 59.4% (38/64) female, and 37.5% (24/64) African American. The study population was notable for numerous comorbid conditions including 95.3% (61/64) hypertension; 50% (32/64) coronary artery disease; 79.7% (51/64) diabetes; and 43.8% (28/64) smoking history. Following PAI intervention for HAIDI, 55 of 64 patients (85.9%) experienced complete resolution of ischemic symptoms; five of 64 patients (7.8%) had partial resolution; two of 64 patients (3.1%) had no resolution, and two of 64 patients (3.1%) had unknown resolution. Primary patency at 1, 12, and 24 months was 94%, 81%, and 71%, respectively. Secondary patency at 1, 12, and 24 months was 97%, 87%, and 84%, respectively. The 30-day complication rate was 10.9% (7/64), with five of 64 (7.8%) thromboses, one of 64 (1.6%) thrombosis and infection, and one of 64 (1.6%) upper extremity swelling secondary to central venous stenosis (resolved with angioplasty of central venous system). Failure rate due to thrombosis at 12 and 24 months was 14% (9/64) and 15.6% (10/64), respectively. CONCLUSIONS: Our study, the largest case series of PAI to date, demonstrates that PAI is a reliable option for HAIDI intervention and has comparable safety and efficacy results to DRIL, despite the use of a synthetic graft. Furthermore, PAI has the added benefit of maintaining the native arterial pathway. Further investigation of PAI is warranted as a promising alternative to DRIL for HAIDI management.
引用
- Bachmann C, Parker M, Sardana T, et al. Proximalization of arterial inflow for treatment of hemodialysis access-induced distal ischemia. J Vasc Surg. 2024. PMID: 38909917. doi:10.1016/j.jvs.2024.05.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。